{"filings":[{"id":1581796,"accession_number":"0001020214-26-000015","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-07-10T20:35:47+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cerus CEO Greenman transitions to Executive Chairman; salary $500K, role through May 2027","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective July 1, 2026, William Greenman becomes Executive Chairman, reporting to Board and CEO.","Annual base salary $500,000; target bonus 80% for 2026, no bonus for 2027.","Role is temporary until May 31, 2027, with ~60% time commitment.","COBRA premium reimbursement if eligible; prior CEO role ended.","Severance eligibility based on new role and compensation per amended agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918677,"accession_number":"0001193125-26-261794","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-06-08T20:20:03+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Cerus enters $65M term loan and $30M revolver, refinancing existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New term loan facility up to $65M; initial $35M drawn to refinance portion of existing term loan.","Additional tranche of $30M available subject to lender approval for working capital.","New revolving credit facility of $30M (expandable to $45M) with $29.9M drawn at closing.","Term loan bears interest at SOFR+5.5% (floor 1%); revolver at SOFR+3.7% (floor 1%).","Existing Amended and Restated Credit Agreements terminated and replaced as of June 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":834076,"accession_number":"0001193125-26-255488","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-06-03T20:17:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Cerus shareholders approve 10M-share increase to equity plan; elect two directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity plan amendment approved: 89.8M for, 42.6M against; adds 10M shares to 2024 Plan reserve.","Directors William M. Greenman and Ann Lucena elected to three-year terms with ~124.7M and ~124.9M votes for.","Advisory say-on-pay approved: 120.9M for (92% of votes cast); 11.0M against, 629,704 abstain.","Ernst & Young ratified as auditor: 164.3M for (98% of votes cast); 2.2M against, 735,277 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90637,"accession_number":"0001193125-26-197129","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q1 revenue up 23% to $59.9M, raises FY product revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $53.7M (+24% YoY); total revenue $59.9M (+23% YoY).","Net loss improved to $1.6M ($0.01/sh) from $7.7M ($0.04/sh) a year ago; Non-GAAP adjusted EBITDA $4.0M vs $0.2M.","Raises full-year 2026 product revenue guidance to $227M-$231M (was $224M-$228M); IFC revenue guided $22M-$24M.","Signed 4-year supply agreement with Établissement Français du Sang (EFS) for INTERCEPT Blood System and INT200.","CEO transition: COO Vivek Jayaraman to become CEO effective July 1, 2026; current CEO William Greenman to become executive chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":53661000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90636,"accession_number":"0001020214-26-000007","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cerus adopts severance plan for top officers; CFO, COO, CMO, CLO covered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Severance plan provides 1.5x-2x salary and bonus multiples, COBRA coverage, and full equity acceleration on change-in-control termination.","Participants: CFO Kevin Green, COO Vivek Jayaraman, CMO Richard Benjamin, CLO Chrystal Jensen.","Non-change-in-control severance for Green, Jensen, and Jayaraman (as COO) includes 12 months base salary and COBRA; Jayaraman as CEO gets enhanced benefits.","Plan supersedes all prior severance arrangements for these officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100324,"accession_number":"0001193125-26-108629","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cerus names Vivek Jayaraman as President and CEO, effective July 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vivek Jayaraman, current COO, will become President and CEO effective July 1, 2026; current CEO Obi Greenman becomes Executive Chairman.","Jayaraman's base salary $740,000; target bonus up to 80% of base salary.","Promotion equity award of $2M (75% time-based RSUs, 25% performance-based RSUs); additional $1M achievement award (performance-based RSUs).","Severance: 12 months base salary plus COBRA continuation and full acceleration of unvested equity upon qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100323,"accession_number":"0001193125-26-085350","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus reports FY2025 revenue $233.8M (+16%); net loss narrows to $15.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 product revenue $206.1M (+14%); total revenue $233.8M (+16%).","Net loss attributable to Cerus $15.6M ($0.08/share) vs $20.9M ($0.11) in 2024.","Non-GAAP adjusted EBITDA $9.5M, up from $5.7M; second consecutive positive year.","IFC demand more than doubled; revenue ~$16.7M (+80%); Q4 U.S. IFC sales $4.2M.","FY2026 product revenue guidance $224M-$228M, representing 9-11% YoY growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100322,"accession_number":"0001193125-26-021085","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Timothy L. Moore not seeking re-election at Cerus 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Moore informed Cerus on Jan 19, 2026 he will not stand for re-election at the 2026 annual meeting.","Decision not due to any disagreement with company operations, policies, or practices.","His term expires at the 2026 annual meeting; no replacement named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100321,"accession_number":"0001193125-26-009824","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus reports preliminary FY 2025 product revenue of $206.1M (+14% YoY); guides FY 2026 to $224-228M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 preliminary product revenue $57.8M, up 14% YoY; IFC revenue $4.2M (+40% YoY).","FY 2025 product revenue $206.1M (+14% YoY); IFC contributed $16.7M (+82% YoY).","FY 2026 product revenue guidance $224-228M (9-11% growth); IFC expected $20-22M.","PMA submission for INT200 LED illumination device expected mid-2026; Phase 3 RBC study results H2 2026.","Complete FY 2025 financial results and business update call planned for early March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":233798000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116657,"accession_number":"0001193125-25-269451","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q3 revenue up 19% to $60.2M, raises FY2025 product revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $52.7M (+15% YoY); total revenue $60.2M (+19% YoY).","GAAP net loss narrowed to $0.02M (near breakeven); non-GAAP adjusted EBITDA $5.0M.","U.S. IFC sales $3.9M, volumes up ~110% YoY; hospital demand increasing.","Full-year 2025 product revenue guidance raised to $202-204M (prev. $200-203M).","Cash and investments $78.5M; generated $1.9M operating cash flow in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133099,"accession_number":"0000950170-25-102976","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q2 product revenue $52.4M (+16% YoY); raises FY2025 guidance to $200-203M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue record $52.4M, up 16% YoY; total revenue $60.1M, up 19% YoY.","Net loss $5.7M ($0.03/sh), narrowing from $5.8M; positive non-GAAP adjusted EBITDA of $0.9M.","IFC revenue $5.6M vs $2.0M prior year; full-year IFC guidance raised to $16-18M (from $12-15M).","Full-year product revenue guidance raised to $200-203M (prior $194-200M) on strong H1 performance.","Cash $78M; DoD awarded $7.2M for lyophilized IFC development; RBC CE Mark under EU review."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149698,"accession_number":"0000950170-25-089029","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cerus board chair Swisher retires; CEO Greenman named chair, Witney lead independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel N. Swisher, Jr., chair of the board, retired effective June 16, 2025; no disagreement with the company.","William M. Greenman, President and CEO, appointed chair of the board effective June 20, 2025.","Frank Witney, Ph.D., appointed lead independent director, effective June 20, 2025.","Swisher also left all board committees upon retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149697,"accession_number":"0000950170-25-083561","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cerus shareholders elect two directors, approve equity plan amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jami Dover Nachtsheim and Hua Shan elected to board with 107.0M and 111.4M votes for, respectively.","Amendment and restatement of 2024 Equity Incentive Plan approved: 74.3M for, 39.5M against.","Advisory say-on-pay vote passed: 104.5M for, 9.3M against, 206K abstentions.","Ernst & Young ratified as independent auditor for FY2025: 153.2M for, 4.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149696,"accession_number":"0000950170-25-061808","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q1 product revenue up 13% to $43.2M; net loss narrows to $7.7M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $43.2M (+13% YoY); total revenue $48.9M incl. $5.6M gov't contract.","Net loss $7.7M ($0.04/sh) vs $9.7M loss ($0.05) prior year; non-GAAP adjusted EBITDA positive $0.2M.","Reiterated FY2025 product revenue guidance $194-$200M (8-11% growth); IFC revenue guidance $12-$15M.","Received CE Mark for INT200 LED illuminator; submitted CE Mark application for INTERCEPT RBC system."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":43239000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168730,"accession_number":"0000950170-25-024125","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus FY2024 product revenue up 15% to $180.3M; GAAP net loss narrows to $20.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue FY2024 $201.3M (+8% YoY); product revenue $180.3M (+15% YoY).","GAAP net loss improved to $20.9M from $37.5M; non-GAAP adjusted EBITDA positive $5.7M vs -$10.7M.","Operating cash flow positive $11.4M for FY2024, an improvement of ~$55M from prior year.","Reiterated FY2025 product revenue guidance of $194M-$200M; IFC revenue guided $12M-$15M.","IFC product revenue grew 42% to $9.2M; Q4 product revenue $50.8M (+9% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":201321000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168729,"accession_number":"0000950170-25-015365","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Gail Schulze to not stand for re-election at Cerus 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gail Schulze notified Cerus on Feb 2, 2025 that she will not stand for re-election.","Her term as director expires at the 2025 annual meeting of stockholders.","Decision not due to any disagreement with Cerus's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168728,"accession_number":"0000950170-25-004588","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus prelim FY2024 product revenue $180.3M (+15% YoY), above guidance; FY2025 guidance $194-200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 product revenue $180.3M, up 15% YoY, exceeding prior guidance of $177-179M.","IFC revenue $9.2M, up 42% YoY.","Q4 product revenue $50.8M, up 9% YoY.","FY2025 product revenue guidance $194-200M (8-11% growth); IFC expected $12-15M.","Q1 2025 growth expected ~10-15% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":201321000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185854,"accession_number":"0000950170-24-134618","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cerus extends supply agreement with Porex through 2027; sets fixed unit pricing for first 24 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Second Amended and Restated Supply and Manufacturing Agreement with Porex, effective Jan 1, 2025.","Extended term of prior agreement to December 31, 2027.","Unit pricing for platelet wafers and plasma disks fixed for first 24 months, then volume-based.","Full agreement text to be filed with 2024 Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185853,"accession_number":"0000950170-24-118948","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q3 product revenue $46.0M (+16% YoY); raises FY2024 guidance to $177-179M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $2.9M ($0.02/sh) from $7.3M; positive non-GAAP adjusted EBITDA of $4.4M.","Product revenue guidance raised to $177-179M from $175-178M; IFC guidance raised to $9-10M.","Signed new 6-year BARDA contract up to $248M for INTERCEPT RBC advancement through PMA licensure.","CE Mark review for INTERCEPT RBCs denied; assessing strategy for resubmission with TÜV-SÜD.","Generated positive operating cash flow for third straight quarter; cash & investments $75.6M at Q3 end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185852,"accession_number":"0001193125-24-238169","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cerus gets $248M BARDA contract for RBC program; EU CE Mark review denied","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New BARDA contract valued up to $248M to support U.S. INTERCEPT RBC system development and PMA submission; $32.1M awarded for base period.","CE Mark review in Europe closed without approval due to insufficient impurity profile data; company assessing strategy for future filing.","RedeS Phase 3 trial enrolling at two new sites; timing of completion and PMA submission under assessment due to later-than-expected site activation.","Company believes positive ReCePI trial data could support broader indication in a future EU CE Mark submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202427,"accession_number":"0000950170-24-089234","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q2 product revenue up 16% to $45M; raises FY2024 guidance to $175-178M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $45.1M (+16% YoY); total revenue $50.5M (+6% YoY).","GAAP net loss narrowed to $5.8M ($0.03/share) from $13.3M loss in Q2 2023.","Non-GAAP adjusted EBITDA turned positive at $0.8M (vs -$4.7M prior year).","Full-year product revenue guidance raised to $175-178M; IFC guidance unchanged at $8-10M.","Canadian Blood Services achieved 100% INTERCEPT platelet adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202426,"accession_number":"0000950170-24-080426","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cerus appoints Dean Gregory to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dean Gregory appointed to Cerus Board, effective July 1, 2024; term expires at 2027 annual meeting.","Gregory is former President, Global Commercial Operations at Fresenius Kabi, with 30+ years in transfusion medicine.","He receives initial RSU of 60,000 shares (3-year vest) and annual cash retainer of $45,000 under director policy.","Gregory's industry expertise expected to support INTERCEPT Blood System expansion and manufacturing capacity growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218558,"accession_number":"0000950170-24-071855","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cerus stockholders approve 2024 equity plan, re-elect three directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Daniel Swisher (102.9M for), Frank Witney (106.9M for), Eric Bjerkholt (91.7M for) to board until 2027.","Approved 2024 Equity Incentive Plan as successor to 2008 plan (103.2M for, 10.7M against).","Approved ESPP amendment increasing authorized shares by 2M (110.6M for).","Advisory vote on executive compensation passed (104.5M for, 9.2M against).","Ratified Ernst & Young as independent auditor for FY2024 (148.3M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218557,"accession_number":"0000950170-24-052053","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q1 product revenue up 24% to $38.4M; net loss narrows to $9.7M; ReCePI trial met endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product revenue $38.4M (+24% YoY); total revenue $43.4M (+13%).","Net loss $9.7M ($0.05 EPS) vs $15.6M ($0.09) in Q1 2023; adjusted EBITDA -$2.7M.","ReCePI Phase 3 trial for INTERCEPT Red Blood Cells met primary endpoint in cardiovascular surgery.","FDA approved 12-month shelf life for INTERCEPT Platelet Processing Sets.","FY2024 product revenue guidance reaffirmed at $172-175M; IFC guidance $8-10M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238450,"accession_number":"0000950170-24-033155","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cerus INTERCEPT RBC Phase 3 trial meets primary non-inferiority endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AKI incidence 29.3% (INTERCEPT RBC) vs 28.0% (conventional); non-inferiority margin 14% (p=0.001).","Related TEAEs within 28 days: 2.5% vs 0.6% (p=0.130); no adverse health effects from RBC antibodies.","Modular PMA submission to FDA planned H2 2025; final module expected H2 2026 after RedeS trial.","ReCePI trial enrolled 581 patients at 18 U.S. sites; funded in part by BARDA contract."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238449,"accession_number":"0000950170-24-025891","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q4 net loss narrows to $1.3M; achieves adj. EBITDA breakeven; reiterates FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss attributable to Cerus narrowed to $1.3M ($0.01/share) from $13.6M ($0.08) a year ago.","Q4 total revenue $53.3M (+4% YoY); product revenue $46.8M (+6% YoY), driven by North America platelet growth.","Achieved Q4 adjusted EBITDA breakeven at +$4.7M vs -$3.7M in Q4 2022.","Reiterated FY2024 product revenue guidance of $172-175M; INTERCEPT Fibrinogen Complex expected $8-10M.","Cash and investments $65.9M at Dec 31; net cash used in ops $43.2M for FY2023, up from $25.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238448,"accession_number":"0000950170-24-002726","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus reports preliminary Q4 product revenue $46.8M; FY 2024 guidance $172-175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 product revenue $46.8M, +6% YoY and +18% sequential; FY 2023 revenue $156.4M in line with guidance.","FY 2024 product revenue guidance $172-175M (10-12% growth); expects adjusted EBITDA breakeven for Q4 2023.","Q1 2024 revenue growth expected in high-teens to low-20s % due to seasonality and unusual Q1 2023 base.","Top-line ReCePI phase 3 readout for INTERCEPT RBCs expected Q1 2024; CE Mark decision anticipated H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":186797000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238447,"accession_number":"0001193125-24-003356","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Cerus removes revenue condition on $5M tranche 3 draw; updates bylaws with exclusive forum provision","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term Loan Amendment eliminates minimum revenue condition for the remaining $5M tranche 3; draw available until July 1, 2024.","Bylaws amended to include exclusive forum: Delaware Chancery for internal corporate matters; federal courts for Securities Act claims.","Bylaws adopt universal proxy rules and update advance notice timing for stockholder nominations and proposals.","For 2024 Annual Meeting, stockholder proposals (non-Rule 14a-8) must be received between Feb 8 and Mar 9, 2024.","Bylaws also clarify remote meeting authority, board postponement power, and limits on director nominations per meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255950,"accession_number":"0000950170-23-058154","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CERS Q3 product revenue $39.8M, net loss $7.3M; FY product revenue guidance cut to $155-158M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 revenue $47.3M ($39.8M product, $7.5M govt); net loss $7.3M ($0.04/share) vs $8.5M loss year ago.","Non-GAAP adjusted EBITDA -$1.0M, improved from -$2.7M; reaffirms Q4 2023 breakeven target.","Full-year 2023 product revenue guidance revised to $155-158M, citing delay in signing IFC sales agreement.","Completed Phase 3 ReCePI study enrollment; top-line data expected Q1 2024.","Cash and investments $79M at Sep 30, down from $102.2M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273353,"accession_number":"0000950170-23-037123","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q2 net loss $13.3M, cuts FY product revenue guidance to $160-165M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $47.7M (product $38.9M, govt $8.9M); net loss $13.3M ($0.07/sh) vs $8.4M loss a year ago.","Full-year 2023 product revenue guidance lowered to $160-165M from $165-170M due to U.S. shelf-life, Europe collections, Russia sanctions.","Recorded $2.1M restructuring charge; expects $10M annual operating expense savings from headcount and real estate reductions.","Non-GAAP adjusted EBITDA negative $4.7M vs negative $2.4M in Q2 2022; cash and investments $84.5M.","INTERCEPT RBC CE Mark decision expected H2 2024; U.S. Phase 3 ReCePI data readout Q1 2024; DoD awarded additional $8.7M for LyoIFC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290301,"accession_number":"0000950170-23-027377","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cerus shareholders elect directors, approve 7M share equity plan increase at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected William M. Greenman (107.8M for), Ann Lucena (114.4M for), Timothy L. Moore (101.7M for) to board until 2026.","Amended equity plan to add 7M shares; approved with 66.5M for, 51.2M against, 32.6M broker non-votes.","Advisory say-on-pay passed with 104.0M for, 13.4M against, 0.3M abstentions.","Ratified Ernst & Young as auditor for FY2023 with 147.3M for, 2.7M against, 0.3M abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290300,"accession_number":"0000950170-23-017869","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q1 revenue down 11% to $38.5M; net loss widens to $15.6M; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $31.0M (-17% YoY) on US inventory drawdown; govt contract revenue $7.5M (+35%).","Net loss $15.6M ($0.09/shr) vs $12.3M ($0.07); adjusted EBITDA -$9.8M vs -$3.7M.","Product gross margin improved to 55.8% (51.7% YoY), fifth consecutive quarter of expansion.","Reiterated FY2023 product revenue guidance $165-170M; expects return to growth as drawdown ends.","Completed debt refinancing; ended Q1 with $94.7M cash, $55M term loan, $18M revolver drawn."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290299,"accession_number":"0001193125-23-092216","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Cerus enters into $75M term loan and $20M revolver credit agreements with MidCap","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $40M (Tranche 1) and $15M (Tranche 2) on closing to refinance existing term loans.","Additional $10M tranches available through July 2025 for working capital.","Revolving facility of $20M (expandable by $15M) with $18M drawn at closing; matures March 2028.","Interest rates: Term SOFR + 6.50% (term loan) and +3.75% (revolver); interest-only for 36 months on term loan.","Covenants include trailing twelve-month minimum net revenue requirement, tested quarterly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311204,"accession_number":"0001193125-23-067785","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cerus confirms no cash deposits or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cerus explicitly states it holds no cash deposits or securities at Silicon Valley Bank.","Statement issued on March 10, 2023, the day SVB was closed by regulators.","Provides reassurance to investors regarding the safety of Cerus' cash position amid banking turmoil."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311203,"accession_number":"0001193125-23-053823","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus reports record Q4 product revenue of $44.0M, up 10% YoY; reiterates FY2023 guidance $165-170M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $44.0M (+10% YoY); full-year product revenue $162.0M (+24% YoY).","Q4 net loss $13.6M ($0.08/sh) vs $9.1M ($0.05/sh) prior year; full-year net loss $42.8M ($0.24/sh) vs $54.4M ($0.32/sh).","Product gross margin Q4 55.7% (record), up from 51.1% prior year; full-year 53.7% vs 51.5%.","Cash and investments $102.2M at Dec 31, 2022; reiterates FY2023 product revenue guidance $165-170M.","Non-GAAP Adjusted EBITDA improved to -$3.7M Q4 from -$4.3M prior year; full-year -$12.4M from -$29.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":188315000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311202,"accession_number":"0001193125-23-004227","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus reports preliminary 2022 product revenue of $162M, up 24% YoY, and guides 2023 revenue $165-170M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2022 product revenue $44.0M, up 10% from Q4 2021.","Full-year 2022 product revenue $162.0M, at top end of guidance, up 24% year-over-year.","2023 product revenue guidance range of $165-170M, citing macroeconomic uncertainty and FX headwinds.","CEO Obi Greenman notes consistent commercial execution and growing demand for INTERCEPT Blood System in U.S.","Company expects 2023 to be a bridge year with uncertainty most acute in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":188315000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329813,"accession_number":"0001193125-22-276881","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q3 revenue up 10% to $46.3M; narrows FY product revenue guidance to $160-162M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $8.5M ($0.05/sh) from $12.4M ($0.07/sh) in Q3 2021.","Product gross margin expanded to 55.4% from 51.3% YoY; adjusted EBITDA loss narrowed to $2.7M.","Cash and investments at $103.8M; net cash used in ops $2.1M vs $6.6M prior year.","Guidance narrowed to $160-162M product revenue from $160-165M, citing FX headwinds.","Awarded $9.1M DoD contract for LyoCryo; Health Canada approved 7-day platelet shelf life."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347391,"accession_number":"0001193125-22-212492","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q2 product revenue $41M (up 30% YoY), net loss narrows to $8.4M; reaffirms FY22 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $47.6M (+26% YoY); product revenue $41.0M (+30% YoY), a company record.","Net loss attributable to Cerus $8.4M ($0.05/share) vs $15.4M loss ($0.09/share) in Q2 2021.","Non-GAAP Adjusted EBITDA improved to -$2.4M from -$8.2M in prior year.","Reiterated FY2022 product revenue guidance $160-165M (22-26% YoY growth).","Cash, cash equivalents, and short-term investments $107.0M at June 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347390,"accession_number":"0001193125-22-187995","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2022-07-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cerus appoints Dr. Hua Shan to Board of Directors effective July 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Hua Shan, Medical Director of Transfusion Medicine at Stanford, joins Cerus Board effective July 1, 2022.","She brings over 25 years of transfusion medicine experience, including expertise in Chinese blood bank practices.","Receives $45k annual cash retainer and initial equity grants valued at $150k in options and $150k in RSUs, vesting over 3 years.","Appointment supports Cerus's JV to bring INTERCEPT Blood System to China and global expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363833,"accession_number":"0001193125-22-166216","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cerus shareholders elect directors, approve equity plan increase of 12M shares at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jami Dover Nachtsheim and Gail Schulze elected to Board with 102.4M and 109.2M votes for, respectively.","Amendment to 2008 Equity Incentive Plan approved: 93.0M for, 22.7M against, adding 12M shares.","Advisory vote on executive compensation passed: 111.5M for, 4.1M against.","Stockholders preferred one-year frequency for future say-on-pay votes: 111.9M voted for one year.","Ratification of Ernst & Young as auditor for FY2022 approved: 142.2M for, 1.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363832,"accession_number":"0001193125-22-142297","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q1 total revenue $43.0M (+46% YoY); raises FY product revenue guidance to $160-165M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $37.4M (+60% YoY) driven by INTERCEPT platelet kit sales in the U.S.","Net loss improved to $12.3M ($0.07/shr) vs $17.5M ($0.10/shr) a year ago.","Non-GAAP Adjusted EBITDA improved to -$3.7M from -$11.5M year-over-year.","Signed multi-year INTERCEPT platelet contract with American Red Cross and 10-year Fresenius Kabi manufacturing extension.","Cash and investments $108.6M at March 31, 2022; net cash used in operations $21.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363831,"accession_number":"0001193125-22-140749","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cerus extends Fresenius supply agreement for INTERCEPT disposables through 2031","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amended and Restated Supply and Manufacturing Agreement signed May 2, 2022, term until Dec 31, 2031.","Fresenius obligated to manufacture finished platelet and plasma disposable kits; Cerus obligated to purchase.","Cerus may source from third parties for supply qualifications or local/regional manufacturing needs.","Fresenius will expand production to three facilities following qualification and licensure.","Pricing based on volume with annual adjustment tied to a price index; standard termination rights apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383582,"accession_number":"0001193125-22-048529","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q4 revenue $50.1M (+49% YoY); reiterates FY2022 product revenue guidance $157-164M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $39.9M (+41% YoY); net loss narrowed to $9.1M ($0.05/sh) from $14.4M.","FY2021 total revenue $159.5M (+40% YoY); product revenue $130.9M (+42% YoY).","FY2022 product revenue guidance reaffirmed at $157-164M, representing 20-25% growth.","Two blood centers obtained BLA approvals for INTERCEPT Fibrinogen Complex (IFC), enabling interstate sales.","Cash, equivalents and short-term investments $129.4M at Dec 31, 2021; net cash used in ops $33.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":159518000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383581,"accession_number":"0001193125-22-005117","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus reports record preliminary Q4/FY2021 product revenue, guides 2022 up 20-25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 preliminary product revenue $39.9M, up 41% YoY from $28.2M.","Full-year 2021 preliminary product revenue $130.9M, above guidance of $127-129M.","2022 product revenue guidance $157-164M, representing 20-25% growth vs. 2021.","More than half of U.S. platelets now treated with INTERCEPT on a run-rate basis.","Nationwide launch of INTERCEPT Fibrinogen Complex after first BLA approval for Gulf Coast blood center."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":159518000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401404,"accession_number":"0001193125-21-366192","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Cerus extends supply deal with Porex to 2024; raises revolver from $10M to $15M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment with Porex extends supply agreement to Dec 31, 2024; unit pricing set for first 12 months with volume-based reductions.","Revolving loan commitments increased from $10M to $15M as of Dec 23, 2021, under amendment with MidCap Funding IV Trust.","Cerus may request an additional $5M increase in revolver commitments, subject to agent and lender approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401403,"accession_number":"0001193125-21-316919","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q3 product revenue $36.1M (+53% YoY); raises FY21 guidance to $127-129M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $42.1M (+44% YoY); product revenue $36.1M (+53% YoY) driven by U.S. INTERCEPT platelet adoption.","Net loss $12.4M ($0.07/shr) improved from $14.1M ($0.08/shr) in Q3 2020.","Product gross margin 51.3% vs 53.6% YoY; gross profit record $18.5M.","FY21 product revenue guidance raised to $127-129M (from $118-122M), representing 38-40% growth.","Cash and short-term investments $120.0M at Sept 30; $55M notes due, $10M revolver drawn."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420364,"accession_number":"0001193125-21-234936","cik":1020214,"company_name":"CERUS CORP","ticker":"CERS","form_type":"8-K","filed_at":"2021-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cerus Q2 revenue $37.8M (+41% YoY); raises FY product revenue guidance to $118-122M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $37.8M (+41% YoY); product revenue $31.5M (+46%) led by 128% North America platelet growth.","FY2021 product revenue guidance raised to $118-122M from $110-114M, representing 28-33% growth over 2020.","Net loss $15.4M ($0.09/sh) vs $14.9M ($0.09) in Q2 2020; cash and investments $122.8M at quarter end.","Submitted PMA supplement for 7-day INTERCEPT platelet storage; final CE Mark module for INTERCEPT red cells.","CMS granted NTAP for INTERCEPT Fibrinogen Complex; initial hospital contracts signed; LifeSouth collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":565040507.6923077,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}